The study compared and contrasted the gene-switching pattern for both plain resveratrol and resveratrol in a matrix with other small molecules (Longevinex) following an induced blockage of circulation in excised animal hearts.
The NIH researchers found that plain resveratrol and Longevinex both protected heart tissues and reduced the size of a heart attack, as measured by the amount of scar tissue (fibrosis).
Longevinex reduced the size of a heart attack (from ~35percent without treatment to ~20percent scar tissue with treatment) while resveratrol (from ~35percent to ~24percent scar tissue), and reduced death of heart muscle cells (cardiomyocytes) from ~17percent without treatment to ~9percent with Longevinex (48percent reduction in cell death), compared to a decline from ~17percent to ~12percent with plain resveratrol (20percent reduction in cell death).
Longevinex also doubled the heart pumping pressure as compared to resveratrol. It also improved blood flow in the aorta more than resveratrol.
MicroRNA's are short segments of RNA that turn off gene protein-making machinery (called gene expression) when microRNA meshes with messenger RNA.
Upon analysis, the study results revealed that Longevinex exerted the greatest influence over the top 25 significantly differentiated microRNA's in rodent heart tissue.
Longevinex exceeded the effect of resveratrol in 15 of the 25 microRNA's.
The study is published in PloS. (ANI)